NHS backs free behavioural change app for type 2 diabeticsNHS England has awarded a contract to tech company Changing Health to develop a free app to help Share XNHS backs free behavioural change app for type 2 diabeticshttps://pharmaphorum.com/news/nhs-backs-free-behavioural-change-app-for-type-2-diabetics/
Celltrion buys drug portfolio from Takeda, ventures into chronic diseasesSouth Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Share XCelltrion buys drug portfolio from Takeda, ventures into chronic diseaseshttps://pharmaphorum.com/news/celltrion-ventures-into-chronic-diseases-with-takeda-portfolio-buy/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
AZ maintains 2020 guidance as Q1 sales grow despite pandemicThe ongoing pandemic will not affect AstraZeneca’s performance in 2020, the company has said after its first quarter results Share XAZ maintains 2020 guidance as Q1 sales grow despite pandemichttps://pharmaphorum.com/news/az-maintains-2020-guidance-as-q1-sales-grow-despite-pandemic/
AstraZeneca on expanding its diabetes research franchiseAstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases. Richard Staines spoke Share XAstraZeneca on expanding its diabetes research franchisehttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/astrazeneca-takes-on-cvrm/
Roche offers free access to diabetes app to relieve pressure on NHSRoche is offering free access to its mySugr Pro diabetes management app in the UK to relieve pressure Share XRoche offers free access to diabetes app to relieve pressure on NHShttps://pharmaphorum.com/news/roche-offers-free-access-to-diabetes-app-during-covid-19/
FDA approves AZ Imfinzi in new lung cancer useAstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, Share XFDA approves AZ Imfinzi in new lung cancer usehttps://pharmaphorum.com/news/fda-approves-az-imfinzi-in-new-lung-cancer-use/
FDA backs Glenmark’s rival to AZ’s blockbuster FarxigaAstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to Share XFDA backs Glenmark’s rival to AZ’s blockbuster Farxigahttps://pharmaphorum.com/news/fda-tentatively-backs-glenmarks-farxiga-generic/
Could GLP-1 drugs treat space headaches? NASA wants to know.Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in Share XCould GLP-1 drugs treat space headaches? NASA wants to know.https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/
